FIT Biotech Oy
Company announcement, December 19, 2016 at 14:30 am EET
FIT BIOTECH’S FINANCIAL INFORMATION SCHEDULE AND AGM 2017
FIT Biotech will report on its financials on the following dates in 2017:
– Full-year financial statements release for 2016 on Friday, March 10, 2017
– Half-year interim report for January-June on Friday, September 15, 2017
The ordinary annual general meeting of shareholders is planned for Friday, April 7, 2017. The company’s Board of Directors will publish a separate notice to the AGM at a later date.
FIT Biotech’s annual report will be published on the company’s website at www.fitbiotech.fi during calendar week 11 / 2017.
FIT Biotech Oy
More information:
Juha Vapaavuori
Chairman of the Board
FIT Biotech Oy
Tel: +358 50 372 0824
E-mail: juha.vapaavuori@sitra.fi
Certified Adviser: Aalto Capital Partners Oy, tel. +358 40 587 7000
FIT Biotech Oy in brief:
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets a significant medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech presently applies the GTU® technology to seven drug development programmes. Examples of application areas include cancer (gene therapy), infectious diseases, such as HIV and tuberculosis, and animal vaccines.
FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq OMX Helsinki Oy.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com
